BPC-157
Other ·Insufficient evidence ·Reviewed May 2026
Synthetic pentadecapeptide marketed for tissue-repair claims. Current human evidence is extremely limited, and FDA flags compounded BPC-157 for limited route-specific safety data and peptide impurity/API characterization concerns.
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
The bottom line
Evidence rating insufficient. Most-documented uses: no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. 2 sources indexed (2025–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Preclinical literature proposes VEGF/nitric-oxide, Akt-eNOS, ERK1/2, angiogenesis, and anti-inflammatory signaling, but these mechanisms have not been validated in large human efficacy or safety trials.1
Dosing & protocol.
Route-specific guidance is intentionally not provided for unapproved research peptides.
Full safety detail.
Side effects
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
Contraindications
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
- Use by competitive athletes subject to anti-doping rules
- Use without clinician supervision
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Reviews & position papers
1- 1Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal HealingSource linkedPMIDMcGuire FP et al. · Curr Rev Musculoskelet Med · 2025
The review describes broad preclinical interest but extremely limited human data and calls for rigorous clinical trials.
Reference material
1- 2Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksSource linkedURLU.S. Food and Drug Administration · FDA · 2026
FDA flags compounded BPC-157 for immunogenicity risk, peptide impurity/API characterization complexity, and limited route-specific safety information.
Deep dives & adjacent profiles.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
BPC-157 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.